<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22470539</article-id><article-id pub-id-type="pmc">3314599</article-id><article-id pub-id-type="publisher-id">PONE-D-11-19454</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0034217</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Anatomy and Physiology</subject><subj-group><subject>Cardiovascular System</subject></subj-group></subj-group><subj-group><subject>Cardiovascular</subject></subj-group><subj-group><subject>Clinical Genetics</subject></subj-group><subj-group><subject>Epidemiology</subject></subj-group></subj-group></article-categories><title-group><article-title>Pharmacogenetic Association of <italic>NOS3</italic> Variants with Cardiovascular Disease in Patients with Hypertension: The GenHAT Study</article-title><alt-title alt-title-type="running-head"><italic>NOS3</italic> Cardiovascular Disease Pharmacogenetics</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xue</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lynch</surname><given-names>Amy I.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>Barry R.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ford</surname><given-names>Charles E.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Boerwinkle</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Eckfeldt</surname><given-names>John H.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Leiendecker-Foster</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Arnett</surname><given-names>Donna K.</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, United States of America</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>School of Public Health, University of Texas-Houston, Houston, Texas, United States of America</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Human Genetics Center Health Science Center at Houston, Houston, Texas, United States of America</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Zhang</surname><given-names>Weili</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">FuWai hospital, Chinese Academy of Medical Sciences, China</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>arnett@uab.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: BRD CEF EB JHE DKA. Performed the experiments: CLF. Analyzed the data: XZ AIL DKA. Wrote the paper: XZ. Interpreted data, gave final approval: XZ. Interpreted data, provided critical input during revision, gave final approval: AIL BRD CEF EB JHE CLF. Interpreted data, provided critical input during drafting and revision, gave final approval: DKA.</p></fn></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>28</day><month>3</month><year>2012</year></pub-date><volume>7</volume><issue>3</issue><elocation-id>e34217</elocation-id><history><date date-type="received"><day>5</day><month>10</month><year>2011</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2012</year></date></history><permissions><copyright-statement>Zhang et al.</copyright-statement><copyright-year>2012</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p>Nitric oxide synthase 3 (NOS3) catalyzes production of NO in the endothelium and may play a role in cardiovascular disease (CVD). We assessed the pharmacogenetic associations of three <italic>NOS3</italic> polymorphisms and three antihypertensive drugs with CVD outcomes. Hypertensive subjects (n&#x0200a;=&#x0200a;30,280) from a multi-center, double-blind clinical trial were randomized to chlorthalidone, amlodipine, or lisinopril treatment (mean follow up, 4.9 years). Outcomes included coronary heart disease (CHD: fatal CHD and nonfatal myocardial infarction); stroke; heart failure (fatal, requiring hospitalization, or outpatient treatment); all-cause mortality; and end-stage renal disease (ESRD). Main effects of <italic>NOS3</italic> variants on outcome and genotype-treatment interactions were tested. For <italic>NOS3</italic> &#x02212;690 C&#x0003e;T (rs3918226), a higher hazard ratio (HR) was found in minor allele carriers for CHD (CC&#x0200a;=&#x0200a;1.00, CT&#x0002b;TT&#x0200a;=&#x0200a;1.12 (95&#x00025; confidence interval (CI)&#x0200a;=&#x0200a;1.00&#x02013;1.26), P&#x0200a;=&#x0200a;0.048). For <italic>NOS3</italic> &#x02212;922 A&#x0003e;G (rs1800779), a higher HR was found in minor allele carriers for heart failure (AA&#x0200a;=&#x0200a;1.00, AG&#x0002b;GG&#x0200a;=&#x0200a;1.10 (CI&#x0200a;=&#x0200a;1.00&#x02013;1.21), P&#x0200a;=&#x0200a;0.046). Significant pharmacogenetic findings were observed for stroke and all-cause mortality. For &#x02212;690 C&#x0003e;T, a lower HR was observed for stroke in minor allele carriers when treated with amlodipine versus lisinopril (CC&#x0200a;=&#x0200a;0.85 (CI&#x0200a;=&#x0200a;0.73&#x02013;0.99), CT&#x0002b;TT&#x0200a;=&#x0200a;0.49 (CI&#x0200a;=&#x0200a;0.31&#x02013;0.80), P&#x0200a;=&#x0200a;0.04). For glu298asp G&#x0003e;T (rs1799983), a lower HR was observed for all-cause mortality in minor allele carriers when treated with amlodipine versus lisinopril (GG&#x0200a;=&#x0200a;1.01 (CI&#x0200a;=&#x0200a;0.91&#x02013;1.13), GT&#x0002b;TT&#x0200a;=&#x0200a;0.85 (CI&#x0200a;=&#x0200a;0.75&#x02013;0.97), P&#x0200a;=&#x0200a;0.04). We observed significant associations with <italic>NOS3</italic> variants and CHD and heart failure and significant pharmacogenetic effects for stroke and all cause mortality. This suggests that <italic>NOS3</italic> variants may potentially provide useful clinical information with respect to treatment decisions in the future.</p></abstract><counts><page-count count="7"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Hypertension is a major risk factor for cardiovascular disease (CVD), a leading cause of mortality worldwide. Control of hypertension is an important priority <xref rid="pone.0034217-Chobanian1" ref-type="bibr">[1]</xref>. Despite improved treatment options, one-third of treated hypertensive patients have blood pressure above target thresholds <xref rid="pone.0034217-Hajjar1" ref-type="bibr">[2]</xref>. One reason for this is that individual response to pharmacologic treatments varies; genetics may be an important determinant of this variable response. Evidence increasingly suggests genetic polymorphisms interact with antihypertensive treatments leading to different blood pressure responses and cardiovascular outcomes <xref rid="pone.0034217-Arnett1" ref-type="bibr">[3]</xref>.</p><p>Given nitric oxide's (NO) role in regulating vascular function, the nitric oxide synthase 3 (endothelial cell) gene (<italic>NOS3</italic>) may play a role in cardiovascular pathology and individual responses to antihypertensive drugs <xref rid="pone.0034217-Cooke1" ref-type="bibr">[4]</xref>. NOS3 catalyzes the production of biological NO, a critical signaling molecule in the relaxation of vascular smooth muscle and vasodilatation. Reduction in basal NO release may predispose humans to hypertension, thrombosis, vasospasm, and atherosclerosis <xref rid="pone.0034217-Oemar1" ref-type="bibr">[5]</xref>. Conversely, overproduction of NO can also damage cells and tissues. Alteration in NO level can be caused by DNA variants that impair the function of NOS3. Many reports have indicated association of <italic>NOS3</italic> polymorphisms with increased occurrence of cardiovascular disease, including coronary artery disease <xref rid="pone.0034217-Colombo1" ref-type="bibr">[6]</xref>, <xref rid="pone.0034217-Colombo2" ref-type="bibr">[7]</xref>, <xref rid="pone.0034217-Chang1" ref-type="bibr">[8]</xref>, <xref rid="pone.0034217-Tangurek1" ref-type="bibr">[9]</xref>, myocardial infarction <xref rid="pone.0034217-Hibi1" ref-type="bibr">[10]</xref>, <xref rid="pone.0034217-Hingorani1" ref-type="bibr">[11]</xref>, hypertension <xref rid="pone.0034217-Miyamoto1" ref-type="bibr">[12]</xref>, <xref rid="pone.0034217-Moe1" ref-type="bibr">[13]</xref>, and stroke <xref rid="pone.0034217-Markus1" ref-type="bibr">[14]</xref>. Despite its pharmacogenetic potential, there are few data regarding the impact of <italic>NOS3</italic> variants on the drug responses in hypertension treatments.</p><p>Amlodipine is a widely prescribed antihypertensive drug. As a calcium channel blocker, amlodipine inhibits the influx of calcium into smooth muscle cells, which is thought to be the major mechanism leading to vasorelaxation. Amlodipine also causes vasodilatation through the activation of NOS3 and subsequent production of NO <xref rid="pone.0034217-Lenasi1" ref-type="bibr">[15]</xref>. Moreover, one of the pathways in NOS3 activation is calcium dependent. This evidence suggests a mechanism of amlodipine action through NOS3.</p><p>In the present study, we tested whether participants in the Genetics of Hypertension Associated Treatment (GenHAT) Study with different <italic>NOS3</italic> genotypes randomized to amlodipine treatment had different outcomes with regard to five CVD measures than their counterparts who were randomized to lisinopril or chlorthalidone. We sought to determine whether there was a detectable pharmacogenetic association of <italic>NOS3</italic> variants with CVD among those randomized to one of these three antihypertensive medications.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Ethics Statement</title><p>Participants recruited during the parent Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) signed informed consent documents; the GenHAT study was approved by the University of Minnesota Institutional Review Board, the University of Alabama at Birmingham Institutional Review Board for Human Use, and the University of Texas Health Science Center at Houston Committee for the Protection of Human Subjects.</p></sec><sec id="s2b"><title>Study Population</title><p>The GenHAT study is ancillary to the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The GenHAT population has been previously described <xref rid="pone.0034217-Lynch1" ref-type="bibr">[16]</xref>. The present study is a subgroup analysis from GenHAT in which 30,280 participants with known genotypes of <italic>NOS3</italic> were analyzed. Approximately half of the participants were women (47&#x00025;), and 61&#x00025; of the participants were white. Participants with missing genotypes were excluded from the analysis; therefore, there were 30,269, 30,239 and 30,240 participants included in the analyses for <italic>NOS3</italic> &#x02212;690 C&#x0003e;T (rs3918226), <italic>NOS3</italic> &#x02212;922 A&#x0003e;G (1800779) and <italic>NOS3</italic> glu298asp G&#x0003e;T (rs1799983), respectively.</p></sec><sec id="s2c"><title>Outcome Ascertainment</title><p>Outcomes of interest in this analysis were coronary heart disease (CHD), including fatal CHD and nonfatal myocardial infarction; stroke; heart failure (fatal, requiring hospitalization, or treated in an outpatient setting); all-cause mortality; and end stage renal disease. Outcomes were reported by clinical investigators. For outcomes involving death, documentation was obtained from death certificates and national databases to identify deaths among participants lost to follow-up. A detailed outcome ascertainment for ALLHAT has been previously published <xref rid="pone.0034217-Davis1" ref-type="bibr">[17]</xref>.</p></sec><sec id="s2d"><title>Genotyping</title><p>DNA samples were collected on FTA paper (Fitzco Inc., Maple Plain, MN) and processed as previously described <xref rid="pone.0034217-deSimone1" ref-type="bibr">[18]</xref>. A multiplex PCR and immobilized probe-based research assay (Roche Molecular Systems, Pleasanton, CA, USA) <xref rid="pone.0034217-Burns1" ref-type="bibr">[19]</xref> was used to genotype the three single-nucleotide polymorphisms (SNPs) listed above. Although the SNPs used in these analyses were chosen because of their availability in the Roche genotyping assay, the variants chosen by Roche were selected on the basis of disease association and functional data available at the time of the assay's design; there is evidence of association with cardiovascular disease in various ethnic and other subgroups for each of the variants <xref rid="pone.0034217-Kullo1" ref-type="bibr">[20]</xref>, <xref rid="pone.0034217-Howard1" ref-type="bibr">[21]</xref>, <xref rid="pone.0034217-Xin1" ref-type="bibr">[22]</xref>. The pairwise linkage disequilibrium R<sup>2</sup> values for the 3 SNPs in the 1000 Genomes CEU population are rs3918226-rs1800779: 0.132; rs3918226-rs1799983: 0.092; rs1800779- rs1799983: 0.137. R<sup>2</sup>s were considerably lower in other race groups.</p></sec><sec id="s2e"><title>Statistical Analysis</title><p>Statistical Analysis Software (SAS), version 9.1 (SAS Institute Inc., Cary, NC) was used for statistical analysis. Hardy-Weinberg (HW) equilibrium tests were performed using chi-square tests. Cox regression was used to test the main effects of <italic>NOS3</italic> genotypes and genotype&#x000d7;treatment interactions on clinical outcomes, resulting in hazard ratios (HRs). In each of the <italic>NOS3</italic> genotypes, the outcomes from amlodipine-treated patients were compared with those from patients treated with chlorthalidone and lisinopril using Cox regression. The main effects of genotypes on outcomes were assessed without or with adjustments for treatment, age, sex, race, Hispanic status, baseline body mass index, diabetes status, baseline total cholesterol, smoking status, and baseline systolic and diastolic blood pressures. The previously published GenHAT design paper <xref rid="pone.0034217-Arnett2" ref-type="bibr">[23]</xref> outlined six primary, <italic>a priori</italic> hypotheses; however, these hypotheses did not include testing the pharmacogenetic effect of <italic>NOS3</italic> variants. Therefore, secondary investigations such as this study are considered exploratory and, as such, are not adjusted for multiple comparisons. Since we performed multiple statistical tests of the pharmacogenetic effects of <italic>NOS3</italic> variants, caution must be exercised in interpreting these findings.</p></sec></sec><sec id="s3"><title>Results</title><p>Baseline characteristics for the 30,280 participants are shown in <xref ref-type="table" rid="pone-0034217-t001">Table 1</xref>. No differences were found in baseline values among treatment groups.</p><table-wrap id="pone-0034217-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0034217.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics for participants (n&#x0200a;=&#x0200a;30,280) by treatment group.</title></caption><alternatives><graphic id="pone-0034217-t001-1" xlink:href="pone.0034217.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Characteristic</td><td align="left" rowspan="1" colspan="1">Amlodipine</td><td align="left" rowspan="1" colspan="1">Lisinopril</td><td align="left" rowspan="1" colspan="1">Chlorthalidone</td><td align="left" rowspan="1" colspan="1">P value<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sample size, n (&#x00025;) by treatment</td><td align="left" rowspan="1" colspan="1">8,178 (27.0)</td><td align="left" rowspan="1" colspan="1">8,237 (27.2)</td><td align="left" rowspan="1" colspan="1">13,865 (45.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (y), mean (SD)</td><td align="left" rowspan="1" colspan="1">66.9 (7.7)</td><td align="left" rowspan="1" colspan="1">66.8 (7.8)</td><td align="left" rowspan="1" colspan="1">66.8 (7.7)</td><td align="left" rowspan="1" colspan="1">0.92</td></tr><tr><td colspan="5" align="left" rowspan="1">Race:</td></tr><tr><td align="left" rowspan="1" colspan="1">White, n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">4,955 (60.6)</td><td align="left" rowspan="1" colspan="1">5,000 (60.7)</td><td align="left" rowspan="1" colspan="1">8,424 (60.8)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">Black, n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">2,834 (34.7)</td><td align="left" rowspan="1" colspan="1">2,828 (34.3)</td><td align="left" rowspan="1" colspan="1">4,741 (34.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">American Indian/Alaskan native, n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">19 (0.2)</td><td align="left" rowspan="1" colspan="1">18 (0.2)</td><td align="left" rowspan="1" colspan="1">27 (0.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Asian/Pacific Islander, n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">96 (1.2)</td><td align="left" rowspan="1" colspan="1">85 (1.0)</td><td align="left" rowspan="1" colspan="1">169 (1.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Other, n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">274 (3.4)</td><td align="left" rowspan="1" colspan="1">306 (3.7)</td><td align="left" rowspan="1" colspan="1">504 (3.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hispanic, n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">1,554 (19.0)</td><td align="left" rowspan="1" colspan="1">1,631 (19.8)</td><td align="left" rowspan="1" colspan="1">2,704 (19.5)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Women, n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">3,891 (47.6)</td><td align="left" rowspan="1" colspan="1">3,819 (46.4)</td><td align="left" rowspan="1" colspan="1">6,518 (47.0)</td><td align="left" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" rowspan="1" colspan="1">On antihypertensive treatment, n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">7,409 (90.6)</td><td align="left" rowspan="1" colspan="1">7,418 (90.1)</td><td align="left" rowspan="1" colspan="1">12,510 (90.2)</td><td align="left" rowspan="1" colspan="1">0.49</td></tr><tr><td colspan="5" align="left" rowspan="1">Blood pressure at baseline:</td></tr><tr><td align="left" rowspan="1" colspan="1">All participants, mm Hg: SBP, mean (SD)</td><td align="left" rowspan="1" colspan="1">146.2 (15.7)</td><td align="left" rowspan="1" colspan="1">146.6 (15.6)</td><td align="left" rowspan="1" colspan="1">146.2 (15.7)</td><td align="left" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP, mean (SD)</td><td align="left" rowspan="1" colspan="1">83.9 (10.2)</td><td align="left" rowspan="1" colspan="1">84.1 (10.0)</td><td align="left" rowspan="1" colspan="1">84.1 (10.1)</td><td align="left" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">Treated at baseline, mm Hg: SBP, mean (SD)</td><td align="left" rowspan="1" colspan="1">145.1 (15.6)</td><td align="left" rowspan="1" colspan="1">145.5 (15.5)</td><td align="left" rowspan="1" colspan="1">145.2 (15.7)</td><td align="left" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP, mean (SD)</td><td align="left" rowspan="1" colspan="1">83.3 (10.1)</td><td align="left" rowspan="1" colspan="1">83.6 (9.9)</td><td align="left" rowspan="1" colspan="1">83.5 (10.0)</td><td align="left" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">Untreated at baseline, mm Hg: SBP, mean (SD)</td><td align="left" rowspan="1" colspan="1">156.5 (12.1)</td><td align="left" rowspan="1" colspan="1">156.4 (12.4)</td><td align="left" rowspan="1" colspan="1">156.1 (12.0)</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP, mean (SD)</td><td align="left" rowspan="1" colspan="1">89.7 (9.6)</td><td align="left" rowspan="1" colspan="1">89.1 (9.3)</td><td align="left" rowspan="1" colspan="1">89.5 (9.0)</td><td align="left" rowspan="1" colspan="1">0.42</td></tr><tr><td colspan="5" align="left" rowspan="1">Eligibility risk factors:</td></tr><tr><td align="left" rowspan="1" colspan="1">Current cigarette smoker, n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">1,805 (22.1)</td><td align="left" rowspan="1" colspan="1">1,803 (21.9)</td><td align="left" rowspan="1" colspan="1">3,056 (22.0)</td><td align="left" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Type 2 diabetes, n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">2,976 (36.4)</td><td align="left" rowspan="1" colspan="1">2,886 (35.0)</td><td align="left" rowspan="1" colspan="1">4,964 (35.8)</td><td align="left" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-C&#x0003c;35 mg/dL, n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">932 (11.4)</td><td align="left" rowspan="1" colspan="1">965 (11.7)</td><td align="left" rowspan="1" colspan="1">1,661 (12.0)</td><td align="left" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" rowspan="1" colspan="1">LVH by electrocardiogram, n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">1,398 (17.1)</td><td align="left" rowspan="1" colspan="1">1,333 (16.2)</td><td align="left" rowspan="1" colspan="1">2,236 (16.1)</td><td align="left" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, mean (SD)</td><td align="left" rowspan="1" colspan="1">29.8 (6.3)</td><td align="left" rowspan="1" colspan="1">29.8 (6.2)</td><td align="left" rowspan="1" colspan="1">29.7 (6.1)</td><td align="left" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting glucose, mean (SD), mg/dL</td><td align="left" rowspan="1" colspan="1">122.9 (57.3)</td><td align="left" rowspan="1" colspan="1">122.4 (55.8)</td><td align="left" rowspan="1" colspan="1">123.3 (58.5)</td><td align="left" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol, mean (SD), mg/dL</td><td align="left" rowspan="1" colspan="1">216.8 (43.9)</td><td align="left" rowspan="1" colspan="1">215.6 (42.2)</td><td align="left" rowspan="1" colspan="1">216.2 (43.5)</td><td align="left" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL cholesterol, mean (SD), mg/dL</td><td align="left" rowspan="1" colspan="1">47.2 (14.7)</td><td align="left" rowspan="1" colspan="1">46.6 (14.6)</td><td align="left" rowspan="1" colspan="1">46.8 (14.9)</td><td align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting triglycerides, mean (SD), mg/dL</td><td align="left" rowspan="1" colspan="1">176.8 (133.0)</td><td align="left" rowspan="1" colspan="1">175.6 (138.9)</td><td align="left" rowspan="1" colspan="1">177.0 (132.5)</td><td align="left" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum creatinine, mean (SD), mg/dL</td><td align="left" rowspan="1" colspan="1">1.01 (0.30)</td><td align="left" rowspan="1" colspan="1">1.02 (0.29)</td><td align="left" rowspan="1" colspan="1">1.02 (0.31)</td><td align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td colspan="5" align="left" rowspan="1">
<italic>NOS3</italic> &#x02212;690 C&#x0003e;T, n (&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">7,244 (88.6)</td><td align="left" rowspan="1" colspan="1">7,293 (88.6)</td><td align="left" rowspan="1" colspan="1">12,306 (88.8)</td><td align="left" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">897 (11.0)</td><td align="left" rowspan="1" colspan="1">905 (11.0)</td><td align="left" rowspan="1" colspan="1">1,477 (10.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">32 (0.4)</td><td align="left" rowspan="1" colspan="1">36 (0.4)</td><td align="left" rowspan="1" colspan="1">79 (0.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1">
<italic>NOS3</italic> &#x02212;922 A&#x0003e;G, n (&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">4,169 (51.1)</td><td align="left" rowspan="1" colspan="1">4,239 (51.5)</td><td align="left" rowspan="1" colspan="1">6,990 (50.5)</td><td align="left" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">AG</td><td align="left" rowspan="1" colspan="1">3,202 (39.3)</td><td align="left" rowspan="1" colspan="1">3,204 (38.9)</td><td align="left" rowspan="1" colspan="1">5,566 (40.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">786 (9.6)</td><td align="left" rowspan="1" colspan="1">787 (9.6)</td><td align="left" rowspan="1" colspan="1">1,296 (9.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1">
<italic>NOS3</italic> glu298asp G&#x0003e;T, n (&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">4,791 (58.6)</td><td align="left" rowspan="1" colspan="1">4,773 (58.0)</td><td align="left" rowspan="1" colspan="1">8,042 (58.1)</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">GT</td><td align="left" rowspan="1" colspan="1">2,761 (33.8)</td><td align="left" rowspan="1" colspan="1">2,852 (34.7)</td><td align="left" rowspan="1" colspan="1">4,853 (35.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">619 (7.6)</td><td align="left" rowspan="1" colspan="1">599 (7.3)</td><td align="left" rowspan="1" colspan="1">950 (6.9)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>&#x0002a;</label><p>test of differences between treatment groups: ANOVA for continuous variables, chi-square for categorical variables. DBP, diastolic blood pressure; HDL-C, HDL cholesterol; LVH, left ventricular hypertrophy; SBP, systolic blood pressure.</p></fn></table-wrap-foot></table-wrap><p>Hardy-Weinberg equilibrium was tested in each race group. <italic>NOS3</italic> &#x02212;690 C&#x0003e;T genotype frequencies were in HW equilibrium in all the race groups. <italic>NOS3</italic> &#x02212;922 A&#x0003e;G genotype frequencies were in HW equilibrium in white, black, American Indian/Alaskan native, and Asian/Pacific islander, but not in the &#x0201c;other race&#x0201d; group (P&#x0200a;=&#x0200a;0.045). <italic>NOS3</italic> glu298asp G&#x0003e;T genotype frequencies were in HW equilibrium in all the groups except whites (P&#x0200a;=&#x0200a;0.0088).</p><sec id="s3a"><title>Main Effect of <italic>NOS3</italic> Variants on Clinical Outcomes</title><p>Hazard ratios for main effects of the <italic>NOS3</italic> variants on clinical outcomes are summarized in <xref ref-type="table" rid="pone-0034217-t002">Table 2</xref>. No association of <italic>NOS3</italic> variants with any clinical outcome was detected when genotypes were analyzed individually (data not shown). When minor allele carriers were combined (CT and CC for <italic>NOS3</italic> &#x02212;690 C&#x0003e;T, AG and GG for <italic>NOS3</italic> &#x02212;922 A&#x0003e;G, GT and TT for <italic>NOS3</italic> glu298asp G&#x0003e;T), associations were found in the adjusted models between <italic>NOS3</italic> &#x02212;690 C&#x0003e;T and CHD, and <italic>NOS3</italic> &#x02212;922 A&#x0003e;G and heart failure (p&#x0003c;0.05). Minor allele carriers of <italic>NOS3</italic> &#x02212;690 C&#x0003e;T have higher risk of CHD (HR, 1.12; 95&#x00025; CI, 1.00&#x02013;1.26) and minor allele carriers of <italic>NOS3</italic> &#x02212;922 A&#x0003e;G have higher risk to heart failure (HR, 1.10; 95&#x00025; CI, 1.00&#x02013;1.21 compared to their respective wild-type homozygous individuals.</p><table-wrap id="pone-0034217-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0034217.t002</object-id><label>Table 2</label><caption><title>Main effects of <italic>NOS3</italic> variants on outcomes, event frequencies and rates, hazard ratios.</title></caption><alternatives><graphic id="pone-0034217-t002-2" xlink:href="pone.0034217.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">
<italic>NOS3</italic> &#x02212;690 C&#x0003e;T</td><td colspan="3" align="left" rowspan="1">
<italic>NOS3</italic> &#x02212;922 A&#x0003e;G</td><td colspan="3" align="left" rowspan="1">
<italic>NOS3</italic> glu298asp G&#x0003e;T</td></tr><tr><td align="left" rowspan="1" colspan="1">Outcome</td><td align="left" rowspan="1" colspan="1">CC (n&#x0200a;=&#x0200a;26,843)</td><td align="left" rowspan="1" colspan="1">CT&#x0002b;TT (n&#x0200a;=&#x0200a;3,426)</td><td align="left" rowspan="1" colspan="1">P value</td><td align="left" rowspan="1" colspan="1">AA (n&#x0200a;=&#x0200a;15,398)</td><td align="left" rowspan="1" colspan="1">AG&#x0002b;GG (n&#x0200a;=&#x0200a;14,841)</td><td align="left" rowspan="1" colspan="1">P value</td><td align="left" rowspan="1" colspan="1">GG (n&#x0200a;=&#x0200a;17,606)</td><td align="left" rowspan="1" colspan="1">GT&#x0002b;TT (n&#x0200a;=&#x0200a;12,634)</td><td align="left" rowspan="1" colspan="1">P value</td></tr></thead><tbody><tr><td colspan="10" align="left" rowspan="1">
<bold>CHD (primary endpoint)</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Event frequency</td><td align="left" rowspan="1" colspan="1">2325</td><td align="left" rowspan="1" colspan="1">354</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1326</td><td align="left" rowspan="1" colspan="1">1350</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1513</td><td align="left" rowspan="1" colspan="1">1163</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Event rate<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">18.8</td><td align="left" rowspan="1" colspan="1">22.7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18.7</td><td align="left" rowspan="1" colspan="1">19.8</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18.7</td><td align="left" rowspan="1" colspan="1">20.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Unadjusted HR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.20 (1.08&#x02013;1.34)</td><td align="left" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.06 (0.98&#x02013;1.14)</td><td align="left" rowspan="1" colspan="1">0.15</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.07 (0.99&#x02013;1.16)</td><td align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Adjusted HR<xref ref-type="table-fn" rid="nt103">&#x02020;</xref> (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.12 (1.00&#x02013;1.26)</td><td align="left" rowspan="1" colspan="1">
<bold>0.048</bold>
</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.98 (0.90&#x02013;1.06)</td><td align="left" rowspan="1" colspan="1">0.62</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.00 (0.92&#x02013;1.08)</td><td align="left" rowspan="1" colspan="1">0.94</td></tr><tr><td colspan="10" align="left" rowspan="1">
<bold>Stroke</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Event frequency</td><td align="left" rowspan="1" colspan="1">1218</td><td align="left" rowspan="1" colspan="1">139</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">720</td><td align="left" rowspan="1" colspan="1">638</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">826</td><td align="left" rowspan="1" colspan="1">531</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Event rate<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">9.8</td><td align="left" rowspan="1" colspan="1">8.7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10.1</td><td align="left" rowspan="1" colspan="1">9.2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10.1</td><td align="left" rowspan="1" colspan="1">9.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Unadjusted HR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.89 (0.75&#x02013;1.06)</td><td align="left" rowspan="1" colspan="1">0.20</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.92 (0.82&#x02013;1.02)</td><td align="left" rowspan="1" colspan="1">0.11</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.89 (0.80&#x02013;0.99)</td><td align="left" rowspan="1" colspan="1">
<bold>0.04</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Adjusted HR<xref ref-type="table-fn" rid="nt103">&#x02020;</xref> (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.96 (0.80&#x02013;1.15)</td><td align="left" rowspan="1" colspan="1">0.63</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.97 (0.86&#x02013;1.09)</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.95 (0.84&#x02013;1.07)</td><td align="left" rowspan="1" colspan="1">0.38</td></tr><tr><td colspan="10" align="left" rowspan="1">
<bold>Heart failure</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Event frequency</td><td align="left" rowspan="1" colspan="1">1769</td><td align="left" rowspan="1" colspan="1">243</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">970</td><td align="left" rowspan="1" colspan="1">1041</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1176</td><td align="left" rowspan="1" colspan="1">833</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Event rate<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">14.3</td><td align="left" rowspan="1" colspan="1">15.4</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">13.7</td><td align="left" rowspan="1" colspan="1">15.3</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">14.5</td><td align="left" rowspan="1" colspan="1">14.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Unadjusted HR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.08 (0.94&#x02013;1.23)</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.12 (1.02&#x02013;1.22)</td><td align="left" rowspan="1" colspan="1">
<bold>0.01</bold>
</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.99 (0.90&#x02013;1.08)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Adjusted HR<xref ref-type="table-fn" rid="nt103">&#x02020;</xref> (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.04 (0.90&#x02013;1.19)</td><td align="left" rowspan="1" colspan="1">0.63</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.10 (1.00&#x02013;1.21)</td><td align="left" rowspan="1" colspan="1">
<bold>0.046</bold>
</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.94 (0.85&#x02013;1.03)</td><td align="left" rowspan="1" colspan="1">0.20</td></tr><tr><td colspan="10" align="left" rowspan="1">
<bold>All-cause mortality</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Event frequency</td><td align="left" rowspan="1" colspan="1">3761</td><td align="left" rowspan="1" colspan="1">498</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2183</td><td align="left" rowspan="1" colspan="1">2069</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2527</td><td align="left" rowspan="1" colspan="1">1728</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Event rate<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">28.6</td><td align="left" rowspan="1" colspan="1">29.7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">28.9</td><td align="left" rowspan="1" colspan="1">28.5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">29.3</td><td align="left" rowspan="1" colspan="1">27.9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Unadjusted HR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.04 (0.95&#x02013;1.14)</td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.99 (0.93&#x02013;1.05)</td><td align="left" rowspan="1" colspan="1">0.64</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.96 (0.90&#x02013;1.02)</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">Adjusted HR<xref ref-type="table-fn" rid="nt103">&#x02020;</xref> (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.05 (0.95&#x02013;1.15)</td><td align="left" rowspan="1" colspan="1">0.37</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.99 (0.93&#x02013;1.05)</td><td align="left" rowspan="1" colspan="1">0.72</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.97 (0.91&#x02013;1.03)</td><td align="left" rowspan="1" colspan="1">0.32</td></tr><tr><td colspan="10" align="left" rowspan="1">
<bold>End-stage renal disease</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Event frequency</td><td align="left" rowspan="1" colspan="1">366</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">214</td><td align="left" rowspan="1" colspan="1">181</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">264</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Event rate<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">2.9</td><td align="left" rowspan="1" colspan="1">1.9</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.9</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.2</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Unadjusted HR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.64 (0.44&#x02013;0.93)</td><td align="left" rowspan="1" colspan="1">
<bold>0.02</bold>
</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.88 (0.72&#x02013;1.07)</td><td align="left" rowspan="1" colspan="1">0.19</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.69 (0.56&#x02013;0.85)</td><td align="left" rowspan="1" colspan="1">
<bold>0.0005</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Adjusted HR<xref ref-type="table-fn" rid="nt103">&#x02020;</xref> (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.84 (0.57&#x02013;1.23)</td><td align="left" rowspan="1" colspan="1">0.36</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">1.09 (0.98&#x02013;1.35)</td><td align="left" rowspan="1" colspan="1">0.44</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.84 (0.67&#x02013;1.06)</td><td align="left" rowspan="1" colspan="1">0.14</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>&#x0002a;per 1000 person-year.</p></fn><fn id="nt103"><label>&#x02020;</label><p>adjusted for treatment, age, sex, race, Hispanic status, baseline BMI, diabetes status, baseline total cholesterol, smoking status, baseline systolic and diastolic blood pressures. CHD, coronary heart disease (including fatal CHD and nonfatal myocardial infarction); CI, confidence interval; HR, hazard ratio.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Pharmacogenetic Association (Genotype&#x000d7;Treatment Interactions) with Clinical Outcomes</title><p>
<xref ref-type="table" rid="pone-0034217-t003">Table 3</xref> summarizes outcome frequencies and rates by genotype group, genotype-specific treatment effects, and the results of pharmacogenetic association tests for amlodipine versus chlorthalidone and amlodipine versus lisinopril. For pharmacogenetic tests, a significant P value for the genotype&#x000d7;treatment interaction indicates that the treatment effects differ by genotypes.</p><table-wrap id="pone-0034217-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0034217.t003</object-id><label>Table 3</label><caption><title>Genotype&#x000d7;treatment interaction results, total events and event rates by genotype and treatment group.</title></caption><alternatives><graphic id="pone-0034217-t003-3" xlink:href="pone.0034217.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">Number of events, event rates per 1000 person-years</td><td colspan="2" align="left" rowspan="1">Genotype-specific treatment effect hazard ratio (95&#x00025;CI)</td><td colspan="2" align="left" rowspan="1">Genotype-by-treatment interaction P values<xref ref-type="table-fn" rid="nt104">&#x0002a;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Outcome - Variant</td><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">AML</td><td align="left" rowspan="1" colspan="1">LIS</td><td align="left" rowspan="1" colspan="1">CHL</td><td align="left" rowspan="1" colspan="1">AML vs. LIS</td><td align="left" rowspan="1" colspan="1">AML vs. CHL</td><td align="left" rowspan="1" colspan="1">AML vs. LIS</td><td align="left" rowspan="1" colspan="1">AML vs. CHL</td></tr></thead><tbody><tr><td colspan="9" align="left" rowspan="1">
<bold>CHD (primary outcome)</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02212;690 C&#x0003e;T</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">642, 19.2</td><td align="left" rowspan="1" colspan="1">618, 18.6</td><td align="left" rowspan="1" colspan="1">1065, 18.8</td><td align="left" rowspan="1" colspan="1">1.03 (0.92&#x02013;1.15)</td><td align="left" rowspan="1" colspan="1">1.02 (0.92&#x02013;1.12)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">89, 20.8</td><td align="left" rowspan="1" colspan="1">90, 21.2</td><td align="left" rowspan="1" colspan="1">175, 24.6</td><td align="left" rowspan="1" colspan="1">0.98(0.73&#x02013;1.32)</td><td align="left" rowspan="1" colspan="1">0.85(0.66&#x02013;1.09)</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02212;922 A&#x0003e;G</td><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">377, 19.6</td><td align="left" rowspan="1" colspan="1">345, 17.8</td><td align="left" rowspan="1" colspan="1">604, 18.8</td><td align="left" rowspan="1" colspan="1">1.10 (0.95&#x02013;1.27)</td><td align="left" rowspan="1" colspan="1">1.04 (0.91&#x02013;1.18)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AG&#x0002b;GG</td><td align="left" rowspan="1" colspan="1">352, 19.1</td><td align="left" rowspan="1" colspan="1">363, 20.0</td><td align="left" rowspan="1" colspan="1">635, 20.1</td><td align="left" rowspan="1" colspan="1">0.95 (0.82&#x02013;1.10)</td><td align="left" rowspan="1" colspan="1">0.95 (0.83&#x02013;1.08)</td><td align="left" rowspan="1" colspan="1">0.17</td><td align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">glu298asp G&#x0003e;T</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">428, 19.3</td><td align="left" rowspan="1" colspan="1">384, 17.6</td><td align="left" rowspan="1" colspan="1">701, 19.0</td><td align="left" rowspan="1" colspan="1">1.10 (0.96&#x02013;1.26)</td><td align="left" rowspan="1" colspan="1">1.02 (0.90&#x02013;1.15)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">303, 19.4</td><td align="left" rowspan="1" colspan="1">323, 20.6</td><td align="left" rowspan="1" colspan="1">537, 20.1</td><td align="left" rowspan="1" colspan="1">0.94 (0.81&#x02013;1.10)</td><td align="left" rowspan="1" colspan="1">0.97 (0.84&#x02013;1.11)</td><td align="left" rowspan="1" colspan="1">0.16</td><td align="left" rowspan="1" colspan="1">0.60</td></tr><tr><td colspan="9" align="left" rowspan="1">
<bold>Stroke</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02212;690 C&#x0003e;T</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">310, 9.1</td><td align="left" rowspan="1" colspan="1">361, 10.7</td><td align="left" rowspan="1" colspan="1">547, 9.5</td><td align="left" rowspan="1" colspan="1">
<bold>0.85 (0.73&#x02013;0.99)</bold>
</td><td align="left" rowspan="1" colspan="1">0.96 (0.83&#x02013;1.10)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">25, 5.7</td><td align="left" rowspan="1" colspan="1">50, 11.6</td><td align="left" rowspan="1" colspan="1">64, 8.7</td><td align="left" rowspan="1" colspan="1">
<bold>0.49 (0.31&#x02013;0.80)</bold>
</td><td align="left" rowspan="1" colspan="1">0.66 (0.42&#x02013;1.05)</td><td align="left" rowspan="1" colspan="1">
<bold>0.04</bold>
</td><td align="left" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02212;922 A&#x0003e;G</td><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">172, 8.8</td><td align="left" rowspan="1" colspan="1">221, 11.3</td><td align="left" rowspan="1" colspan="1">327, 10.1</td><td align="left" rowspan="1" colspan="1">0.78 (0.64&#x02013;0.95)</td><td align="left" rowspan="1" colspan="1">0.87 (0.72&#x02013;1.05)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AG&#x0002b;GG</td><td align="left" rowspan="1" colspan="1">164, 8.8</td><td align="left" rowspan="1" colspan="1">190, 10.3</td><td align="left" rowspan="1" colspan="1">284, 8.8</td><td align="left" rowspan="1" colspan="1">0.85 (0.69&#x02013;1.05)</td><td align="left" rowspan="1" colspan="1">0.99 (0.82&#x02013;1.20)</td><td align="left" rowspan="1" colspan="1">0.56</td><td align="left" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1">glu298asp G&#x0003e;T</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">217, 9.7</td><td align="left" rowspan="1" colspan="1">241, 11.0</td><td align="left" rowspan="1" colspan="1">368, 9.9</td><td align="left" rowspan="1" colspan="1">0.88 (0.73&#x02013;1.06)</td><td align="left" rowspan="1" colspan="1">0.98 (0.83&#x02013;1.16)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">118, 7.4</td><td align="left" rowspan="1" colspan="1">170, 10.7</td><td align="left" rowspan="1" colspan="1">243, 8.9</td><td align="left" rowspan="1" colspan="1">0.70 (0.55&#x02013;0.88)</td><td align="left" rowspan="1" colspan="1">0.83 (0.67&#x02013;1.04)</td><td align="left" rowspan="1" colspan="1">0.12</td><td align="left" rowspan="1" colspan="1">0.24</td></tr><tr><td colspan="9" align="left" rowspan="1">
<bold>Heart failure</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02212;690 C&#x0003e;T</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">582, 17.4</td><td align="left" rowspan="1" colspan="1">490, 14.8</td><td align="left" rowspan="1" colspan="1">697, 12.2</td><td align="left" rowspan="1" colspan="1">1.18 (1.05&#x02013;1.33)</td><td align="left" rowspan="1" colspan="1">1.43 (1.28&#x02013;1.59)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">73, 17.1</td><td align="left" rowspan="1" colspan="1">72, 16.9</td><td align="left" rowspan="1" colspan="1">98, 13.6</td><td align="left" rowspan="1" colspan="1">1.02 (0.74&#x02013;1.42)</td><td align="left" rowspan="1" colspan="1">1.27 (0.94&#x02013;1.72)</td><td align="left" rowspan="1" colspan="1">0.40</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02212;922 A&#x0003e;G</td><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">317, 16.5</td><td align="left" rowspan="1" colspan="1">270, 13.9</td><td align="left" rowspan="1" colspan="1">383, 11.8</td><td align="left" rowspan="1" colspan="1">1.18 (1.01&#x02013;1.39)</td><td align="left" rowspan="1" colspan="1">1.39 (1.20&#x02013;1.61)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AG&#x0002b;GG</td><td align="left" rowspan="1" colspan="1">337, 18.4</td><td align="left" rowspan="1" colspan="1">292, 16.2</td><td align="left" rowspan="1" colspan="1">412, 12.9</td><td align="left" rowspan="1" colspan="1">1.14 (0.97&#x02013;1.33)</td><td align="left" rowspan="1" colspan="1">1.42 (1.24&#x02013;1.65)</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">0.80</td></tr><tr><td align="left" rowspan="1" colspan="1">glu298asp G&#x0003e;T</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">403, 18.3</td><td align="left" rowspan="1" colspan="1">325, 14.9</td><td align="left" rowspan="1" colspan="1">448, 12.0</td><td align="left" rowspan="1" colspan="1">1.22 (1.06&#x02013;1.42)</td><td align="left" rowspan="1" colspan="1">1.52 (1.33&#x02013;1.74)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">252, 16.1</td><td align="left" rowspan="1" colspan="1">237, 15.1</td><td align="left" rowspan="1" colspan="1">344, 12.8</td><td align="left" rowspan="1" colspan="1">1.07 (0.90&#x02013;1.28)</td><td align="left" rowspan="1" colspan="1">1.27 (1.08&#x02013;1.49)</td><td align="left" rowspan="1" colspan="1">0.25</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td colspan="9" align="left" rowspan="1">
<bold>All-cause mortality</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02212;690 C&#x0003e;T</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">977, 27.4</td><td align="left" rowspan="1" colspan="1">1027, 28.8</td><td align="left" rowspan="1" colspan="1">1757, 29.1</td><td align="left" rowspan="1" colspan="1">0.95 (0.87&#x02013;1.04)</td><td align="left" rowspan="1" colspan="1">0.94 (0.87&#x02013;1.01)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">135, 29.7</td><td align="left" rowspan="1" colspan="1">148, 32.4</td><td align="left" rowspan="1" colspan="1">215, 28.1</td><td align="left" rowspan="1" colspan="1">0.93 (0.73&#x02013;1.17)</td><td align="left" rowspan="1" colspan="1">1.07 (0.86&#x02013;1.33)</td><td align="left" rowspan="1" colspan="1">0.82</td><td align="left" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02212;922 A&#x0003e;G</td><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">575, 28.0</td><td align="left" rowspan="1" colspan="1">602, 28.9</td><td align="left" rowspan="1" colspan="1">1006, 29.4</td><td align="left" rowspan="1" colspan="1">0.97 (0.86&#x02013;1.08)</td><td align="left" rowspan="1" colspan="1">0.95 (0.86&#x02013;1.05)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AG&#x0002b;GG</td><td align="left" rowspan="1" colspan="1">534, 27.3</td><td align="left" rowspan="1" colspan="1">572, 29.4</td><td align="left" rowspan="1" colspan="1">963, 28.6</td><td align="left" rowspan="1" colspan="1">0.93 (0.82&#x02013;1.04)</td><td align="left" rowspan="1" colspan="1">0.95 (0.86&#x02013;1.06)</td><td align="left" rowspan="1" colspan="1">0.61</td><td align="left" rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" rowspan="1" colspan="1">glu298asp G&#x0003e;T</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">687, 29.1</td><td align="left" rowspan="1" colspan="1">670, 28.7</td><td align="left" rowspan="1" colspan="1">1170, 29.7</td><td align="left" rowspan="1" colspan="1">
<bold>1.01 (0.91&#x02013;1.13)</bold>
</td><td align="left" rowspan="1" colspan="1">0.98 (0.89&#x02013;1.08)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">425, 25.6</td><td align="left" rowspan="1" colspan="1">505, 30.0</td><td align="left" rowspan="1" colspan="1">798, 28.1</td><td align="left" rowspan="1" colspan="1">
<bold>0.85 (0.75&#x02013;0.97)</bold>
</td><td align="left" rowspan="1" colspan="1">0.91 (0.81&#x02013;1.03)</td><td align="left" rowspan="1" colspan="1">
<bold>0.04</bold>
</td><td align="left" rowspan="1" colspan="1">0.36</td></tr><tr><td colspan="9" align="left" rowspan="1">
<bold>End-stage renal disease</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02212;690 C&#x0003e;T</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">105, 3.0</td><td align="left" rowspan="1" colspan="1">102, 3.0</td><td align="left" rowspan="1" colspan="1">159, 2.7</td><td align="left" rowspan="1" colspan="1">1.02 (0.78&#x02013;1.34)</td><td align="left" rowspan="1" colspan="1">1.11 (0.87&#x02013;1.42)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">7, 1.6</td><td align="left" rowspan="1" colspan="1">10, 2.3</td><td align="left" rowspan="1" colspan="1">13, 1.8</td><td align="left" rowspan="1" colspan="1">0.70 (0.27&#x02013;1.85)</td><td align="left" rowspan="1" colspan="1">0.91 (0.36&#x02013;2.29)</td><td align="left" rowspan="1" colspan="1">0.46</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02212;922 A&#x0003e;G</td><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">63, 3.2</td><td align="left" rowspan="1" colspan="1">59, 3.0</td><td align="left" rowspan="1" colspan="1">92, 2.8</td><td align="left" rowspan="1" colspan="1">1.07 (0.75&#x02013;1.53)</td><td align="left" rowspan="1" colspan="1">1.14 (0.82&#x02013;1.57)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AG&#x0002b;GG</td><td align="left" rowspan="1" colspan="1">47, 2.5</td><td align="left" rowspan="1" colspan="1">54, 2.9</td><td align="left" rowspan="1" colspan="1">80, 2.5</td><td align="left" rowspan="1" colspan="1">0.85 (0.58&#x02013;1.26)</td><td align="left" rowspan="1" colspan="1">1.01 (0.70&#x02013;1.44)</td><td align="left" rowspan="1" colspan="1">0.40</td><td align="left" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">glu298asp G&#x0003e;T</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">77, 3.4</td><td align="left" rowspan="1" colspan="1">73, 3.3</td><td align="left" rowspan="1" colspan="1">114, 3.0</td><td align="left" rowspan="1" colspan="1">1.04 (0.75&#x02013;1.43)</td><td align="left" rowspan="1" colspan="1">1.12 (0.84&#x02013;1.50)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">35, 2.2</td><td align="left" rowspan="1" colspan="1">39, 2.4</td><td align="left" rowspan="1" colspan="1">57, 2.1</td><td align="left" rowspan="1" colspan="1">0.90 (0.57&#x02013;1.43)</td><td align="left" rowspan="1" colspan="1">1.05 (0.69&#x02013;1.60)</td><td align="left" rowspan="1" colspan="1">0.63</td><td align="left" rowspan="1" colspan="1">0.80</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label/><p>&#x0002a;P value: minor allele carriers combined into one group due to low numbers of events in some cells, H<sub>o</sub>&#x0200a;=&#x0200a;interaction coefficient equals zero (1-degree of freedom test). AML, amlodipine; CHD, coronary heart disease (including fatal CHD and nonfatal myocardial infarction), CHL, chlorthalidone; CI, confidence interval; LIS, lisinopril.</p></fn></table-wrap-foot></table-wrap><p>Our data suggested a pharmacogenetic association for the &#x02212;690 C&#x0003e;T variant with stroke, and for the glu298asp G&#x0003e;T with all-cause mortality when comparing amlodipine with lisinopril. When treated with amlodipine vs. lisinopril, the minor allele carriers at the <italic>NOS3</italic> &#x02212;690 locus showed lower risk of stroke (HR, 0.49 vs. 0.85; 95&#x00025; CI, 0.31&#x02013;0.80 vs. 0.73&#x02013;0.99; P&#x0200a;=&#x0200a;0.04), and the minor allele carriers at the glu298asp locus showed lower risk of all-cause mortality (HR, 0.85 vs. 1.01; 95&#x00025; CI, 0.75&#x02013;0.97 vs. 0.91&#x02013;1.13, P&#x0200a;=&#x0200a;0.04) compared to their respective wild type homozygous individuals.</p></sec></sec><sec id="s4"><title>Discussion</title><p>NO is a critical signaling molecule in many physiological and pathological processes. Three NO synthase (NOS) enzymes have been identified, which catalyze the production of biological NO from L-arginine. Primarily expressed in endothelia, the NOS3 enzyme has been proposed to be the most relevant NOS in vasodilatation and vascular diseases. Sequence variations have been reported since the cloning of <italic>NOS3</italic>; variations may result in reduced or excessive production of NO and contribute to cardiovascular diseases <xref rid="pone.0034217-Wang1" ref-type="bibr">[24]</xref>. In the present study, we examined the association of the <italic>NOS3</italic> variants &#x02212;690 C&#x0003e;T, &#x02212;922 A&#x0003e;G, and glu298asp G&#x0003e;T with five CVD outcomes. Association was detected between &#x02212;690 C&#x0003e;T and CHD, &#x02212;922 A&#x0003e;G and heart failure. We also compared the pharmacogenetic effects in amlodipine group versus lisinopril and chlorthalidone groups. Our data suggest that minor allele carriers for &#x02212;690 C&#x0003e;T and glu298asp G&#x0003e;T may have lower risk of stroke and all-cause mortality when using amlodipine as compared to lisinopril.</p><p>As one of the polymorphisms in the coding region of <italic>NOS3</italic>, the glu298asp G&#x0003e;T variant has been studied extensively. This G-to-T transversion at nucleotide position 894 within exon 7 results in a change of glutamate to aspartate at position 298 in the oxygenase domain of the NOS3 protein. Associations between the glu298asp G&#x0003e;T polymorphism and NO synthesis <xref rid="pone.0034217-Persu1" ref-type="bibr">[25]</xref>, <xref rid="pone.0034217-Tesauro1" ref-type="bibr">[26]</xref> and endothelial function <xref rid="pone.0034217-Savvidou1" ref-type="bibr">[27]</xref>, <xref rid="pone.0034217-Leeson1" ref-type="bibr">[28]</xref> have been previously described. The change of glutamate to aspartate may affect the interaction of NOS3 with caveolin-1, thereby affecting the localization of NOS3 and, eventually, diminishing the activation of NOS3 <xref rid="pone.0034217-Joshi1" ref-type="bibr">[29]</xref>. Molecular studies suggested that, even though intact NOS3 Asp298 has equivalent enzymatic activity to NOS3 Glu298, carriers of NOS3 Asp298 may be at different disease risk if exposed to adverse environmental influence on endothelial function <xref rid="pone.0034217-Hingorani2" ref-type="bibr">[30]</xref>. Epidemiologic studies have associated this polymorphism with the development of hypertension <xref rid="pone.0034217-Benjafield1" ref-type="bibr">[31]</xref>, CHD, and endothelial dysfunction <xref rid="pone.0034217-Leeson1" ref-type="bibr">[28]</xref>. Glu298asp G&#x0003e;T may also play a role in renal function. GG carriers were reported to have lower mean arterial pressure and an augmented glomerular filtration rate than the homozygotes for the wild type allele <xref rid="pone.0034217-Cherney1" ref-type="bibr">[32]</xref>. In response to a graded L-arginine infusion, the GG carriers had significant changes in effective renal plasma flow, glomerular filtration rate, filtration fraction, renal vascular resistance, and renal blood flow. In contrast, the renal response to L-arginine in GT/TT carriers was blunted. Epidemiologic studies, however, reported inconsistent results on the association between glu298asp and end-stage renal disease. This may be partly due to different cohorts chosen in different studies. Although several studies suggested the T allele is the risk allele for end-stage renal disease <xref rid="pone.0034217-Noiri1" ref-type="bibr">[33]</xref>, <xref rid="pone.0034217-Thaha1" ref-type="bibr">[34]</xref>, <xref rid="pone.0034217-Nagase1" ref-type="bibr">[35]</xref>, <xref rid="pone.0034217-Suzuki1" ref-type="bibr">[36]</xref>, others reported that homozygosity for the G allele was associated with increased risk with diabetic nephropathy <xref rid="pone.0034217-Mollsten1" ref-type="bibr">[37]</xref>, or showed no association with ESRD <xref rid="pone.0034217-DellOmo1" ref-type="bibr">[38]</xref>. Our study did not find statistical evidence that the T allele was associated with a lower risk of end-stage renal disease in hypertensive patients.</p><p>Variations in the promoter regions of <italic>NOS3</italic> have also been identified, among which are &#x02212;922A/G and &#x02212;690C/T. Although these variations are not located in the catalytic site or consensus sequences for transcription factor binding <xref rid="pone.0034217-Wang1" ref-type="bibr">[24]</xref>, <xref rid="pone.0034217-Fischmann1" ref-type="bibr">[39]</xref>, they may affect the protein level and enzyme activity through regulation of gene expression, thereby affecting the plasma NO metabolite levels <xref rid="pone.0034217-Jachymova1" ref-type="bibr">[40]</xref>, blood pressure, and risk of cardiovascular diseases. A recent genome-wide association study of essential hypertension singled out &#x02212;690 C&#x0003e;T as potentially playing a role in hypertension. Not only were hypertension associations with the polymorphism genome-wide significant in a 2-stage case-control study, the finding was confirmed in a 21,714-subject meta-analysis. Using PATCH, the authors identified a putative binding site for ETS family transcription factors directly next to the &#x02212;690 C&#x0003e;T locus. ETS-1 and ELF-1 are essential factors for activation of the <italic>NOS3</italic> promoter, suggesting that this variant might modulate the transcription of <italic>NOS3</italic>
<xref rid="pone.0034217-Salvi1" ref-type="bibr">[41]</xref>. Our study showed that minor allele carriers for &#x02212;690 C&#x0003e;T have higher risk in CHD, and minor allele carriers for &#x02212;922 A&#x0003e;G have higher risk in heart failure (<xref ref-type="table" rid="pone-0034217-t002">Table 2</xref>). The &#x02212;786 T&#x0003e;C (rs2070744) polymorphism is the most studied variant in <italic>NOS3</italic> promoter. The C allele has been associated with reduced promoter activity and gene transcription <xref rid="pone.0034217-Augeri1" ref-type="bibr">[42]</xref> and may influence the risk of cardiovascular events <xref rid="pone.0034217-Colombo1" ref-type="bibr">[6]</xref>, <xref rid="pone.0034217-Asakimori1" ref-type="bibr">[43]</xref>, cardiovascular mortality <xref rid="pone.0034217-Rossi1" ref-type="bibr">[44]</xref>, and hypertension and CVD in renal allograft recipients <xref rid="pone.0034217-Bhandary1" ref-type="bibr">[45]</xref>. This SNP is in strong linkage disequilibrium with &#x02212;922A&#x0003e;G (In 1000 Genomes sample, R<sup>2</sup>&#x0200a;=&#x0200a;0.967 in CEU, R<sup>2</sup>&#x0200a;=&#x0200a;1.00 in YRI.) It is not clear if these two variants affect the risk of CVD through altering the <italic>NOS3</italic> transcription and NO level. More functional studies are needed to elucidate the mechanisms of &#x02212;690 C&#x0003e;T and &#x02212;922 A&#x0003e;G in the development of heart disease outcomes.</p><p>In the present study, we also tested whether subjects with different <italic>NOS3</italic> genotypes randomized to the amlodipine had different outcomes than their counterparts who were randomized to lisinopril or chlorthalidone. Significant genotype&#x000d7;treatment interactions were observed for stroke and all-cause mortality when comparing amlodipine to lisinopril. CC and TT genotypes for &#x02212;690 C&#x0003e;T have a lower risk of stroke, while GT and TT genotypes for glu298asp have a lower risk of all-cause mortality. Because <italic>NOS3</italic> glu298asp G&#x0003e;T genotype frequencies were not in HW equilibrium in whites (P&#x0200a;=&#x0200a;0.0088), we further stratified the white group into Hispanic whites and non-Hispanic whites and found HW equilibrium P values were 0.49 and 0.004, respectively. The all-cause mortality interaction ratio of hazard ratios (and P values) for the amlodipine versus lisinopril comparison for this variant for the combined race analysis (as reported in <xref ref-type="table" rid="pone-0034217-t003">Table 3</xref>), the non-Hispanic whites, and the Hispanic whites were 0.84 (P&#x0200a;=&#x0200a;0.04), 0.79 (P&#x0200a;=&#x0200a;0.04), and 0.88 (P&#x0200a;=&#x0200a;0.35), respectively. This suggests the lack of HW equilibrium in the non-Hispanic white group is not responsible for the overall pharmacogenetic association. The randomized design of the trial minimizes admixture as a possible confounder (i.e., degree of admixture would be the same in treatment groups).</p><p>It has been reported that amlodipine may cause vasodilatation through the activation of NOS3 <xref rid="pone.0034217-Lenasi1" ref-type="bibr">[15]</xref>. It is known that one of the pathways in NOS3 activation is calcium dependent. Since amlodipine blocks the efflux of Ca, it may also deactivate NOS3 through Ca regulation. How these two actions of amlodipine on NOS3 interact is unknown. In our analyses of CVD outcomes, minor allele carriers tend to have more favorable outcomes when randomized to amlodipine versus lisinopril, but not amlodipine versus chlorthalidone, which suggests <italic>NOS3</italic> variants may be useful in some, but not all, antihypertensive treatment decisions.</p><p>For our suggestive pharmacogenetic findings, we used linear regression to determine if there was an equivalent pharmacogenetic association with change in systolic blood pressure and change in diastolic blood pressure (&#x00394;SBP, &#x00394;DBP respectively; that is, blood pressure at randomization minus blood pressure 6 months after randomization) for the stroke/<italic>NOS3</italic> &#x02212;690 C&#x0003e;T and all-cause mortality/<italic>NOS3</italic> glu298asp G&#x0003e;T findings. This could suggest a mechanistic pathway with which to explain the interaction for outcome events. There was, however, no equivalent association (P&#x0200a;=&#x0200a;0.77 and P&#x0200a;=&#x0200a;0.78 for &#x00394;SBP and &#x00394;DBP, respectively, for the stroke findings; P&#x0200a;=&#x0200a;0.07 and P&#x0200a;=&#x0200a;0.59 for &#x00394;SBP and &#x00394;DBP, respectively, for the all-cause mortality findings).</p><p>By using a large cohort of hypertensive patients, our study suggested pharmocogenetic associations of <italic>NOS3</italic> variants with CVD outcomes, and demonstrated the importance of genetic information in individualized therapy.</p><p>Because GenHAT's parent ALLHAT population included only older, hypertensive participants with other risk factors for CVD, caution must be used in generalizing these findings to younger, healthier populations. In addition, because we interrogated the 23,529-base pair <italic>NOS3</italic> at only 3 SNP loci, this study is not a complete evaluation of the pharmacogenetic effects of <italic>NOS3</italic>. Although it is plausible that the polymorphisms investigated here directly influence vascular function, variants with main or pharmacogenetic effects cannot be assumed causal for CVD outcomes. Because we performed multiple tests of pharmacogenetic effects, these findings would not meet the strictest threshold of statistical significance if corrected for multiple testing (e.g., Bonferroni correction: 0.05/30 tests would equate to a P value of 0.0017).</p><sec id="s4a"><title>Conclusions</title><p>Findings from this randomized, double-blind clinical trial suggest that there are associations between <italic>NOS3</italic> variants and CHD and heart failure, as well as pharmacogenetic associations for the &#x02212;690 C&#x0003e;T variant of <italic>NOS3</italic> with stroke, and for the glu298asp G&#x0003e;T variant with all-cause mortality when comparing amlodipine with lisinopril. The pharmacogenetic comparison of amlodipine versus chlorthalidone reported here suggests that consideration of these <italic>NOS3</italic> variants does not impinge upon ALLHAT's general recommendation of chlorthalidone as a first-step therapy. However, our suggestive pharmacogenetic associations argue for future genetic and functional studies to confirm our findings and explore the implications of <italic>NOS3</italic> genetic variation in hypertension treatment with respect to cardiovascular outcomes.</p></sec></sec></body><back><ack><p>The authors thank the Human Genetics Department at Roche Molecular Systems, Inc for genotyping reagents and technical support.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by National Heart, Lung and Blood Institute grants HL63082 (GenHAT - Genetics of Hypertension Associated Treatments: ClinicalTrials.gov, NCT00006294, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00006294">http://clinicaltrials.gov/ct2/show/NCT00006294</ext-link>) and N01-HC-35130 (ALLHAT - Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: ClinicalTrials.gov, NCT00000542, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00000542">http://clinicaltrials.gov/ct2/show/NCT00000542</ext-link>). The National Heart, Lung, and Blood Institute had a contributing role in the analysis and interpretation of the ALLHAT data.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0034217-Chobanian1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chobanian</surname><given-names>AV</given-names></name></person-group>
<year>2001</year>
<article-title>Control of hypertension&#x02013;an important national priority.</article-title>
<source>N Engl J Med</source>
<volume>345</volume>
<fpage>534</fpage>
<lpage>535</lpage>
<pub-id pub-id-type="pmid">11519509</pub-id></element-citation></ref><ref id="pone.0034217-Hajjar1"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hajjar</surname><given-names>I</given-names></name><name><surname>Kotchen</surname><given-names>TA</given-names></name></person-group>
<year>2003</year>
<article-title>Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988&#x02013;2000.</article-title>
<source>Jama</source>
<volume>290</volume>
<fpage>199</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="pmid">12851274</pub-id></element-citation></ref><ref id="pone.0034217-Arnett1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arnett</surname><given-names>DK</given-names></name><name><surname>Claas</surname><given-names>SA</given-names></name><name><surname>Glasser</surname><given-names>SP</given-names></name></person-group>
<year>2006</year>
<article-title>Pharmacogenetics of antihypertensive treatment.</article-title>
<source>Vascul Pharmacol</source>
<volume>44</volume>
<fpage>107</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="pmid">16356784</pub-id></element-citation></ref><ref id="pone.0034217-Cooke1"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cooke</surname><given-names>GE</given-names></name><name><surname>Doshi</surname><given-names>A</given-names></name><name><surname>Binkley</surname><given-names>PF</given-names></name></person-group>
<year>2007</year>
<article-title>Endothelial nitric oxide synthase gene: prospects for treatment of heart disease.</article-title>
<source>Pharmacogenomics</source>
<volume>8</volume>
<fpage>1723</fpage>
<lpage>1734</lpage>
<pub-id pub-id-type="pmid">18086002</pub-id></element-citation></ref><ref id="pone.0034217-Oemar1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oemar</surname><given-names>BS</given-names></name><name><surname>Tschudi</surname><given-names>MR</given-names></name><name><surname>Godoy</surname><given-names>N</given-names></name><name><surname>Brovkovich</surname><given-names>V</given-names></name><name><surname>Malinski</surname><given-names>T</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis.</article-title>
<source>Circulation</source>
<volume>97</volume>
<fpage>2494</fpage>
<lpage>2498</lpage>
<pub-id pub-id-type="pmid">9657467</pub-id></element-citation></ref><ref id="pone.0034217-Colombo1"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Colombo</surname><given-names>MG</given-names></name><name><surname>Paradossi</surname><given-names>U</given-names></name><name><surname>Andreassi</surname><given-names>MG</given-names></name><name><surname>Botto</surname><given-names>N</given-names></name><name><surname>Manfredi</surname><given-names>S</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease.</article-title>
<source>Clin Chem</source>
<volume>49</volume>
<fpage>389</fpage>
<lpage>395</lpage>
<pub-id pub-id-type="pmid">12600950</pub-id></element-citation></ref><ref id="pone.0034217-Colombo2"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Colombo</surname><given-names>MG</given-names></name><name><surname>Andreassi</surname><given-names>MG</given-names></name><name><surname>Paradossi</surname><given-names>U</given-names></name><name><surname>Botto</surname><given-names>N</given-names></name><name><surname>Manfredi</surname><given-names>S</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Evidence for association of a common variant of the endothelial nitric oxide synthase gene (Glu298&#x02013;&#x0003e;Asp polymorphism) to the presence, extent, and severity of coronary artery disease.</article-title>
<source>Heart</source>
<volume>87</volume>
<fpage>525</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="pmid">12010932</pub-id></element-citation></ref><ref id="pone.0034217-Chang1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>K</given-names></name><name><surname>Baek</surname><given-names>SH</given-names></name><name><surname>Seung</surname><given-names>KB</given-names></name><name><surname>Kim</surname><given-names>PJ</given-names></name><name><surname>Ihm</surname><given-names>SH</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>The Glu298Asp polymorphism in the endothelial nitric oxide synthase gene is strongly associated with coronary spasm.</article-title>
<source>Coron Artery Dis</source>
<volume>14</volume>
<fpage>293</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="pmid">12826928</pub-id></element-citation></ref><ref id="pone.0034217-Tangurek1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tangurek</surname><given-names>B</given-names></name><name><surname>Ozer</surname><given-names>N</given-names></name><name><surname>Sayar</surname><given-names>N</given-names></name><name><surname>Terzi</surname><given-names>S</given-names></name><name><surname>Yilmaz</surname><given-names>H</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>The relationship between endothelial nitric oxide synthase gene polymorphism (T-786 C) and coronary artery disease in the Turkish population.</article-title>
<source>Heart Vessels</source>
<volume>21</volume>
<fpage>285</fpage>
<lpage>290</lpage>
<pub-id pub-id-type="pmid">17151815</pub-id></element-citation></ref><ref id="pone.0034217-Hibi1"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hibi</surname><given-names>K</given-names></name><name><surname>Ishigami</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Mizushima</surname><given-names>S</given-names></name><name><surname>Nyui</surname><given-names>N</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction.</article-title>
<source>Hypertension</source>
<volume>32</volume>
<fpage>521</fpage>
<lpage>526</lpage>
<pub-id pub-id-type="pmid">9740620</pub-id></element-citation></ref><ref id="pone.0034217-Hingorani1"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hingorani</surname><given-names>AD</given-names></name><name><surname>Liang</surname><given-names>CF</given-names></name><name><surname>Fatibene</surname><given-names>J</given-names></name><name><surname>Lyon</surname><given-names>A</given-names></name><name><surname>Monteith</surname><given-names>S</given-names></name><etal/></person-group>
<year>1999</year>
<article-title>A common variant of the endothelial nitric oxide synthase (Glu298&#x02013;&#x0003e;Asp) is a major risk factor for coronary artery disease in the UK.</article-title>
<source>Circulation</source>
<volume>100</volume>
<fpage>1515</fpage>
<lpage>1520</lpage>
<pub-id pub-id-type="pmid">10510054</pub-id></element-citation></ref><ref id="pone.0034217-Miyamoto1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Kajiyama</surname><given-names>N</given-names></name><name><surname>Yoshimura</surname><given-names>M</given-names></name><name><surname>Shimasaki</surname><given-names>Y</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Endothelial nitric oxide synthase gene is positively associated with essential hypertension.</article-title>
<source>Hypertension</source>
<volume>32</volume>
<fpage>3</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">9674630</pub-id></element-citation></ref><ref id="pone.0034217-Moe1"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moe</surname><given-names>KT</given-names></name><name><surname>Lim</surname><given-names>ST</given-names></name><name><surname>Wong</surname><given-names>P</given-names></name><name><surname>Chua</surname><given-names>T</given-names></name><name><surname>DeSilva</surname><given-names>DA</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Association analysis of endothelial nitric oxide synthase gene polymorphism with primary hypertension in a Singapore population.</article-title>
<source>J Hum Hypertens</source>
<volume>20</volume>
<fpage>956</fpage>
<lpage>963</lpage>
<pub-id pub-id-type="pmid">17024134</pub-id></element-citation></ref><ref id="pone.0034217-Markus1"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Markus</surname><given-names>HS</given-names></name><name><surname>Ruigrok</surname><given-names>Y</given-names></name><name><surname>Ali</surname><given-names>N</given-names></name><name><surname>Powell</surname><given-names>JF</given-names></name></person-group>
<year>1998</year>
<article-title>Endothelial nitric oxide synthase exon 7 polymorphism, ischemic cerebrovascular disease, and carotid atheroma.</article-title>
<source>Stroke</source>
<volume>29</volume>
<fpage>1908</fpage>
<lpage>1911</lpage>
<pub-id pub-id-type="pmid">9731617</pub-id></element-citation></ref><ref id="pone.0034217-Lenasi1"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lenasi</surname><given-names>H</given-names></name><name><surname>Kohlstedt</surname><given-names>K</given-names></name><name><surname>Fichtlscherer</surname><given-names>B</given-names></name><name><surname>Mulsch</surname><given-names>A</given-names></name><name><surname>Busse</surname><given-names>R</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495.</article-title>
<source>Cardiovasc Res</source>
<volume>59</volume>
<fpage>844</fpage>
<lpage>853</lpage>
<pub-id pub-id-type="pmid">14553824</pub-id></element-citation></ref><ref id="pone.0034217-Lynch1"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lynch</surname><given-names>AI</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Davis</surname><given-names>BR</given-names></name><name><surname>Ford</surname><given-names>CE</given-names></name><name><surname>Eckfeldt</surname><given-names>JH</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.</article-title>
<source>Jama</source>
<volume>299</volume>
<fpage>296</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="pmid">18212314</pub-id></element-citation></ref><ref id="pone.0034217-Davis1"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davis</surname><given-names>BR</given-names></name><name><surname>Cutler</surname><given-names>JA</given-names></name><name><surname>Gordon</surname><given-names>DJ</given-names></name><name><surname>Furberg</surname><given-names>CD</given-names></name><name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></name><etal/></person-group>
<year>1996</year>
<article-title>Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.</article-title>
<source>Am J Hypertens</source>
<volume>9</volume>
<fpage>342</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="pmid">8722437</pub-id></element-citation></ref><ref id="pone.0034217-deSimone1"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Simone</surname><given-names>G</given-names></name><name><surname>Palmieri</surname><given-names>V</given-names></name><name><surname>Bella</surname><given-names>JN</given-names></name><name><surname>Celentano</surname><given-names>A</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study.</article-title>
<source>J Hypertens</source>
<volume>20</volume>
<fpage>323</fpage>
<lpage>331</lpage>
<pub-id pub-id-type="pmid">11821719</pub-id></element-citation></ref><ref id="pone.0034217-Burns1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burns</surname><given-names>JC</given-names></name><name><surname>Shimizu</surname><given-names>C</given-names></name><name><surname>Shike</surname><given-names>H</given-names></name><name><surname>Newburger</surname><given-names>JW</given-names></name><name><surname>Sundel</surname><given-names>RP</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease.</article-title>
<source>Genes Immun</source>
<volume>6</volume>
<fpage>438</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="pmid">15889128</pub-id></element-citation></ref><ref id="pone.0034217-Kullo1"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kullo</surname><given-names>IJ</given-names></name><name><surname>Greene</surname><given-names>MT</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Chu</surname><given-names>J</given-names></name><name><surname>Turner</surname><given-names>ST</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Association of polymorphisms in NOS3 with the ankle-brachial index in hypertensive adults.</article-title>
<source>Atherosclerosis</source>
<volume>196</volume>
<fpage>905</fpage>
<lpage>912</lpage>
<pub-id pub-id-type="pmid">17367796</pub-id></element-citation></ref><ref id="pone.0034217-Howard1"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Howard</surname><given-names>TD</given-names></name><name><surname>Giles</surname><given-names>WH</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Wozniak</surname><given-names>MA</given-names></name><name><surname>Malarcher</surname><given-names>AM</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Promoter polymorphisms in the nitric oxide synthase 3 gene are associated with ischemic stroke susceptibility in young black women.</article-title>
<source>Stroke</source>
<volume>36</volume>
<fpage>1848</fpage>
<lpage>1851</lpage>
<pub-id pub-id-type="pmid">16100023</pub-id></element-citation></ref><ref id="pone.0034217-Xin1"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xin</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Xue</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>A common variant of the eNOS gene (E298D) is an independent risk factor for left ventricular hypertrophy in human essential hypertension.</article-title>
<source>Clin Sci (Lond)</source>
<volume>117</volume>
<fpage>67</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="pmid">19132956</pub-id></element-citation></ref><ref id="pone.0034217-Arnett2"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arnett</surname><given-names>DK</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Davis</surname><given-names>BR</given-names></name><name><surname>Eckfeldt</surname><given-names>J</given-names></name><name><surname>Ford</surname><given-names>CE</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study.</article-title>
<source>Pharmacogenomics J</source>
<volume>2</volume>
<fpage>309</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="pmid">12439737</pub-id></element-citation></ref><ref id="pone.0034217-Wang1"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group>
<year>2000</year>
<article-title>Endothelial nitric oxide synthase gene sequence variations and vascular disease.</article-title>
<source>Mol Genet Metab</source>
<volume>70</volume>
<fpage>241</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="pmid">10993711</pub-id></element-citation></ref><ref id="pone.0034217-Persu1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Persu</surname><given-names>A</given-names></name><name><surname>Stoenoiu</surname><given-names>MS</given-names></name><name><surname>Messiaen</surname><given-names>T</given-names></name><name><surname>Davila</surname><given-names>S</given-names></name><name><surname>Robino</surname><given-names>C</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Modifier effect of ENOS in autosomal dominant polycystic kidney disease.</article-title>
<source>Hum Mol Genet</source>
<volume>11</volume>
<fpage>229</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="pmid">11823442</pub-id></element-citation></ref><ref id="pone.0034217-Tesauro1"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tesauro</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>WC</given-names></name><name><surname>Rogliani</surname><given-names>P</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Chaudhary</surname><given-names>PP</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>97</volume>
<fpage>2832</fpage>
<lpage>2835</lpage>
<pub-id pub-id-type="pmid">10717002</pub-id></element-citation></ref><ref id="pone.0034217-Savvidou1"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Savvidou</surname><given-names>MD</given-names></name><name><surname>Vallance</surname><given-names>PJ</given-names></name><name><surname>Nicolaides</surname><given-names>KH</given-names></name><name><surname>Hingorani</surname><given-names>AD</given-names></name></person-group>
<year>2001</year>
<article-title>Endothelial nitric oxide synthase gene polymorphism and maternal vascular adaptation to pregnancy.</article-title>
<source>Hypertension</source>
<volume>38</volume>
<fpage>1289</fpage>
<lpage>1293</lpage>
<pub-id pub-id-type="pmid">11751705</pub-id></element-citation></ref><ref id="pone.0034217-Leeson1"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leeson</surname><given-names>CP</given-names></name><name><surname>Hingorani</surname><given-names>AD</given-names></name><name><surname>Mullen</surname><given-names>MJ</given-names></name><name><surname>Jeerooburkhan</surname><given-names>N</given-names></name><name><surname>Kattenhorn</surname><given-names>M</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function.</article-title>
<source>Circ Res</source>
<volume>90</volume>
<fpage>1153</fpage>
<lpage>1158</lpage>
<pub-id pub-id-type="pmid">12065317</pub-id></element-citation></ref><ref id="pone.0034217-Joshi1"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Joshi</surname><given-names>MS</given-names></name><name><surname>Bauer</surname><given-names>JA</given-names></name></person-group>
<year>2008</year>
<article-title>Preliminary computational modeling of nitric oxide synthase 3 interactions with caveolin-1: influence of exon 7 Glu298Asp polymorphism.</article-title>
<source>Acta Biochim Biophys Sin (Shanghai)</source>
<volume>40</volume>
<fpage>47</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="pmid">18180853</pub-id></element-citation></ref><ref id="pone.0034217-Hingorani2"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hingorani</surname><given-names>AD</given-names></name></person-group>
<year>2003</year>
<article-title>Endothelial nitric oxide synthase polymorphisms and hypertension.</article-title>
<source>Curr Hypertens Rep</source>
<volume>5</volume>
<fpage>19</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="pmid">12530931</pub-id></element-citation></ref><ref id="pone.0034217-Benjafield1"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benjafield</surname><given-names>AV</given-names></name><name><surname>Morris</surname><given-names>BJ</given-names></name></person-group>
<year>2000</year>
<article-title>Association analyses of endothelial nitric oxide synthase gene polymorphisms in essential hypertension.</article-title>
<source>Am J Hypertens</source>
<volume>13</volume>
<fpage>994</fpage>
<lpage>998</lpage>
<pub-id pub-id-type="pmid">10981549</pub-id></element-citation></ref><ref id="pone.0034217-Cherney1"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cherney</surname><given-names>DZ</given-names></name><name><surname>Scholey</surname><given-names>JW</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zimpelmann</surname><given-names>J</given-names></name><name><surname>Kennedy</surname><given-names>C</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Endothelial nitric oxide synthase gene polymorphisms and the renal hemodynamic response to L-arginine.</article-title>
<source>Kidney Int</source>
<volume>75</volume>
<fpage>327</fpage>
<lpage>332</lpage>
<pub-id pub-id-type="pmid">19037250</pub-id></element-citation></ref><ref id="pone.0034217-Noiri1"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noiri</surname><given-names>E</given-names></name><name><surname>Satoh</surname><given-names>H</given-names></name><name><surname>Taguchi</surname><given-names>J</given-names></name><name><surname>Brodsky</surname><given-names>SV</given-names></name><name><surname>Nakao</surname><given-names>A</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Association of eNOS Glu298Asp polymorphism with end-stage renal disease.</article-title>
<source>Hypertension</source>
<volume>40</volume>
<fpage>535</fpage>
<lpage>540</lpage>
<pub-id pub-id-type="pmid">12364359</pub-id></element-citation></ref><ref id="pone.0034217-Thaha1"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thaha</surname><given-names>M</given-names></name><name><surname>Pranawa</surname></name><name><surname>Yogiantoro</surname><given-names>M</given-names></name><name><surname>Sutjipto</surname></name><name><surname>Sunarjo</surname></name><etal/></person-group>
<year>2008</year>
<article-title>Association of endothelial nitric oxide synthase Glu298Asp polymorphism with end-stage renal disease.</article-title>
<source>Clin Nephrol</source>
<volume>70</volume>
<fpage>144</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="pmid">18793530</pub-id></element-citation></ref><ref id="pone.0034217-Nagase1"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nagase</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Kikuchi</surname><given-names>S</given-names></name><name><surname>Hirayama</surname><given-names>A</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Association of ecNOS gene polymorphisms with end stage renal diseases.</article-title>
<source>Mol Cell Biochem</source>
<volume>244</volume>
<fpage>113</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="pmid">12701818</pub-id></element-citation></ref><ref id="pone.0034217-Suzuki1"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Nagase</surname><given-names>S</given-names></name><name><surname>Kikuchi</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Koyama</surname><given-names>A</given-names></name></person-group>
<year>2000</year>
<article-title>Association of a missense Glu298Asp mutation of the endothelial nitric oxide synthase gene with end stage renal disease.</article-title>
<source>Clin Chem</source>
<volume>46</volume>
<fpage>1858</fpage>
<lpage>1860</lpage>
<pub-id pub-id-type="pmid">11067831</pub-id></element-citation></ref><ref id="pone.0034217-Mollsten1"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mollsten</surname><given-names>A</given-names></name><name><surname>Wessman</surname><given-names>M</given-names></name><name><surname>Svensson</surname><given-names>M</given-names></name><name><surname>Forsblom</surname><given-names>C</given-names></name><name><surname>Parkkonen</surname><given-names>M</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Glu298Asp and NOS4ab polymorphisms in diabetic nephropathy.</article-title>
<source>Ann Med</source>
<volume>38</volume>
<fpage>522</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="pmid">17101543</pub-id></element-citation></ref><ref id="pone.0034217-DellOmo1"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dell'Omo</surname><given-names>G</given-names></name><name><surname>Penno</surname><given-names>G</given-names></name><name><surname>Pucci</surname><given-names>L</given-names></name><name><surname>Fotino</surname><given-names>C</given-names></name><name><surname>Lucchesi</surname><given-names>D</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men.</article-title>
<source>J Hypertens</source>
<volume>25</volume>
<fpage>1389</fpage>
<lpage>1395</lpage>
<pub-id pub-id-type="pmid">17563560</pub-id></element-citation></ref><ref id="pone.0034217-Fischmann1"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fischmann</surname><given-names>TO</given-names></name><name><surname>Hruza</surname><given-names>A</given-names></name><name><surname>Niu</surname><given-names>XD</given-names></name><name><surname>Fossetta</surname><given-names>JD</given-names></name><name><surname>Lunn</surname><given-names>CA</given-names></name><etal/></person-group>
<year>1999</year>
<article-title>Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation.</article-title>
<source>Nat Struct Biol</source>
<volume>6</volume>
<fpage>233</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="pmid">10074942</pub-id></element-citation></ref><ref id="pone.0034217-Jachymova1"><label>40</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jachymova</surname><given-names>M</given-names></name><name><surname>Horky</surname><given-names>K</given-names></name><name><surname>Bultas</surname><given-names>J</given-names></name><name><surname>Kozich</surname><given-names>V</given-names></name><name><surname>Jindra</surname><given-names>A</given-names></name><etal/></person-group>
<year>2001</year>
<article-title>Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy.</article-title>
<source>Biochem Biophys Res Commun</source>
<volume>284</volume>
<fpage>426</fpage>
<lpage>430</lpage>
<pub-id pub-id-type="pmid">11394896</pub-id></element-citation></ref><ref id="pone.0034217-Salvi1"><label>41</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salvi</surname><given-names>E</given-names></name><name><surname>Kutalik</surname><given-names>Z</given-names></name><name><surname>Glorioso</surname><given-names>N</given-names></name><name><surname>Benaglio</surname><given-names>P</given-names></name><name><surname>Frau</surname><given-names>F</given-names></name><etal/></person-group>
<year>2012</year>
<article-title>Genomewide Association Study Using a High-Density Single Nucleotide Polymorphism Array and Case-Control Design Identifies a Novel Essential Hypertension Susceptibility Locus in the Promoter Region of Endothelial NO Synthase.</article-title>
<source>Hypertension</source>
<volume>59</volume>
<fpage>248</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="pmid">22184326</pub-id></element-citation></ref><ref id="pone.0034217-Augeri1"><label>42</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Augeri</surname><given-names>AL</given-names></name><name><surname>Tsongalis</surname><given-names>GJ</given-names></name><name><surname>Van Heest</surname><given-names>JL</given-names></name><name><surname>Maresh</surname><given-names>CM</given-names></name><name><surname>Thompson</surname><given-names>PD</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>The endothelial nitric oxide synthase &#x02212;786 T&#x0003e;C polymorphism and the exercise-induced blood pressure and nitric oxide responses among men with elevated blood pressure.</article-title>
<source>Atherosclerosis</source>
<volume>204</volume>
<fpage>e28</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">19155013</pub-id></element-citation></ref><ref id="pone.0034217-Asakimori1"><label>43</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Asakimori</surname><given-names>Y</given-names></name><name><surname>Yorioka</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>J</given-names></name><name><surname>Takasugi</surname><given-names>N</given-names></name><name><surname>Harada</surname><given-names>S</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Association between ENOS gene polymorphism and cardiovascular events in nondiabetic hemodialysis patients: a prospective study.</article-title>
<source>Am J Kidney Dis</source>
<volume>44</volume>
<fpage>112</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="pmid">15211444</pub-id></element-citation></ref><ref id="pone.0034217-Rossi1"><label>44</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rossi</surname><given-names>GP</given-names></name><name><surname>Maiolino</surname><given-names>G</given-names></name><name><surname>Zanchetta</surname><given-names>M</given-names></name><name><surname>Sticchi</surname><given-names>D</given-names></name><name><surname>Pedon</surname><given-names>L</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>The T(&#x02212;786)C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high-risk patients.</article-title>
<source>J Am Coll Cardiol</source>
<volume>48</volume>
<fpage>1166</fpage>
<lpage>1174</lpage>
<pub-id pub-id-type="pmid">16979000</pub-id></element-citation></ref><ref id="pone.0034217-Bhandary1"><label>45</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhandary</surname><given-names>UV</given-names></name><name><surname>Tse</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Knowles</surname><given-names>MR</given-names></name><name><surname>Demaine</surname><given-names>AG</given-names></name></person-group>
<year>2008</year>
<article-title>Endothelial nitric oxide synthase polymorphisms are associated with hypertension and cardiovascular disease in renal transplantation.</article-title>
<source>Nephrology (Carlton)</source>
<volume>13</volume>
<fpage>348</fpage>
<lpage>355</lpage>
<pub-id pub-id-type="pmid">18331440</pub-id></element-citation></ref></ref-list></back></article>